glp-1 obesity drug news today oct 23 2025 Compound versions of drugs for weight loss halted by FDA Obesity GLP-1 Market

Despite the potential clinical benefits of GLP-1RA plus SGLT2i combination therapy in patients with T2DM, several factors may delay this combination to become a common practice soon, such as reimbursement and costs associated with polypharmacy

Learn why it happens and discover Strive's Digest, a science-backed supplement for gentle, effective relief

From a scientific breakthrough studying the oft fasting Gila Monster has become the current successful weight loss therapies, here's how.

Molecular communications in the gutbrain axis, between the central nervous system and the gastrointestinal tract, are critical for maintaining healthy brain function, particularly in aging

The product also includes BCAAs, which not only support muscle endurance but also contribute to a healthier gut environment by supporting digestive health

Overall, the study supports current guideline flexibility, indicating that both GLP-1RAs and SGLT2 inhibitors provide broadly similar cardiovascular protection